Skip to navigation Skip to main content

XALKORI® (crizotinib) for Locally Advanced or Metastatic ALK+ NSCLC

Slideshow

  • Xalkori 1

  • Xalkori 2

  • Xalkori 3

  • Xalkori 4

  • Xalkori 5

  • Xalkori 6

  • Xalkori 7

  • Xalkori 8

  • Xalkori 9

  • Xalkori 10

  • Xalkori 11

  • Xalkori 12

  • Xalkori 13

  • Xalkori 14

  • Xalkori 15

  • Xalkori 16

  • Xalkori_29

  • Xalkori_28

  • Xalkori_27

  • Xalkori_26

  • Xalkori_25

  • Xalkori_24

  • Xalkori_23

  • Xalkori_22

  • Xalkori_21

  • Xalkori_20

  • Xalkori_19

  • Xalkori_18

  • Xalkori_17

This slideshow reviews drug information for XALKORI® (crizotinib), indicated for locally advanced or metastatic ALK+NSCLC.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: Use in Specific Populations
Slide 10: Clinical Pharmacology
Slide 15: Warnings and Precautions
Slide 19: Clinical Safety and Efficacy
Slide 27: Drug Storage and Supply
Slide 29: References

Topics:

Drug Showcase Lung Cancer Non-Small Cell Lung Cancer
  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More

Next hm-slideshow in Slides